Cargando…

Is there an oncological benefit to extended lymphadenectomy for muscle-invasive bladder cancer?

The full optimal extent of a pelvic lymph node dissection (PLND) at time of radical cystectomy (RC) has not yet been determined. The diagnostic role of LND is clear and is extremely important for identifying those who may benefit from adjuvant therapy. While retrospective analyses have demonstrated...

Descripción completa

Detalles Bibliográficos
Autores principales:	Clinton, Timothy N., Huang, Chun, Goh, Alvin C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Review Article on Muscle-Invasive Bladder Cancer
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7807354/ https://www.ncbi.nlm.nih.gov/pubmed/33457268 http://dx.doi.org/10.21037/tau-20-406

Ejemplares similares

Where are we now and where are we heading in muscle invasive bladder cancer
por: Ku, Ja Hyeon, et al.
Publicado: (2020)

Bladder-sparing protocols in the treatment of muscle-invasive bladder cancer
por: Tholomier, Côme, et al.
Publicado: (2020)

Perioperative immunotherapy for muscle-invasive bladder cancer
por: Kim, In-Ho, et al.
Publicado: (2020)

Tumor heterogeneity in muscle-invasive bladder cancer
por: Kang, Ho Won, et al.
Publicado: (2020)

Role of PET/CT in muscle-invasive bladder cancer
por: Kim, Seok-ki
Publicado: (2020)

The optimal management of variant histology in muscle invasive bladder cancer
por: Tiwari, Raj Vikesh, et al.
Publicado: (2020)

Partial cystectomy for muscle-invasive bladder cancer: a review of the literature
por: Peak, Taylor C., et al.
Publicado: (2020)

Update on bladder cancer molecular subtypes
por: Fong, Megan Hoi Yan, et al.
Publicado: (2020)

Role of magnetic resonance imaging in tumor staging and follow-up for bladder cancer
por: Sim, Ki Choon, et al.
Publicado: (2020)

Enhanced recovery after surgery of patients undergoing radical cystectomy for bladder cancer
por: Sung, Luck Hee, et al.
Publicado: (2020)

Review of the evidence for robotic-assisted robotic cystectomy and intra-corporeal urinary diversion in bladder cancer
por: Brodie, Andrew, et al.
Publicado: (2020)

Outcomes for Muscle-invasive Bladder Cancer with Radical Cystectomy or Trimodal Therapy in US Veterans
por: Kumar, Abhishek, et al.
Publicado: (2021)

Bladder-sparing Treatment in Patients with Bacillus Calmette-Guerin–unresponsive Non–muscle-invasive Bladder Cancer: An Analysis of Long-term Survival Outcomes
por: Tan, Wei Shen, et al.
Publicado: (2023)

Role of Serum Lymphocyte-derived Biomarkers in Nonmetastatic Muscle-invasive Bladder Cancer Patients Treated with Trimodal Therapy
por: Kool, Ronald, et al.
Publicado: (2021)

Development of the First Patient-centred Set of Outcomes for Muscle-invasive and Metastatic Bladder Cancer: A Multicentre Initiative
por: Reesink, Daan J., et al.
Publicado: (2021)

Trial-based Cost-effectiveness Analysis of an Immediate Postoperative Mitomycin C Instillation in Patients with Non–muscle-invasive Bladder Cancer
por: Hentschel, Anouk E., et al.
Publicado: (2022)

Partial Versus Complete Bacillus Calmette-Guérin Intravesical Therapy and Bladder Cancer Outcomes in High-risk Non–muscle-invasive Bladder Cancer: Is NIMBUS the Full Story?
por: Rezaee, Michael E., et al.
Publicado: (2021)

Feasibility and Impact of Immunohistochemistry-based Molecular Subtyping for Muscle-invasive Bladder Cancer in Patients Treated with Radiation-based Therapy
por: Hesswani, Charles, et al.
Publicado: (2023)

A Multicenter Retrospective Cohort Series of Muscle-invasive Bladder Cancer Patients Treated with Definitive Concurrent Chemoradiotherapy in Daily Practice
por: de Ruiter, Ben-Max, et al.
Publicado: (2022)

Health-related quality of life after radical cystectomy
por: Choi, Hoon, et al.
Publicado: (2020)

Patient Preferences for Treatment of Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer: A Cross-country Choice Experiment
por: Collacott, Hannah, et al.
Publicado: (2023)

Validation and Reliability Testing of the EORTC QLQ-NMIBC24 Questionnaire Module to Assess Patient-reported Outcomes in Non–Muscle-invasive Bladder Cancer
por: Blazeby, Jane M., et al.
Publicado: (2014)

SPTAN1, APC, and FGFR3 Mutation Status and APOBEC Mutation Signatures are Predictive of Mitomycin C Response in Non-muscle-invasive Bladder Cancer
por: Lindgren, Maria Skydt, et al.
Publicado: (2021)

A Phase 1b Clinical Study of Intravesical Photodynamic Therapy in Patients with Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer
por: Kulkarni, Girish S., et al.
Publicado: (2022)

Photodynamic Diagnosis-guided Transurethral Resection of Bladder Tumour in Participants with a First Suspected Diagnosis of Intermediate- or High-risk Non–muscle-invasive Bladder Cancer: Cost-effectiveness Analysis Alongside a Randomised Controlled Trial
por: Yu, Ge, et al.
Publicado: (2023)

Sexual Dimorphism in Outcomes of Non–muscle-invasive Bladder Cancer: A Role of CD163+ Macrophages, B cells, and PD-L1 Immune Checkpoint
por: Chenard, Stephen, et al.
Publicado: (2021)

Quality of Life in Patients with High-grade Non–muscle-invasive Bladder Cancer Undergoing Standard Versus Reduced Frequency of Bacillus Calmette-Guérin Instillations: The EAU-RF NIMBUS Trial
por: van Straten, Christine G.J.I., et al.
Publicado: (2023)

The Use of Urine Mycobacterium tuberculosis Complex Polymerase Chain Reaction as a Predictive Factor for Recurrence and Progression After Intravesical Bacillus Calmette-Guérin Therapy in Patients with Non–muscle‑invasive Bladder Cancer
por: Muto, Satoru, et al.
Publicado: (2021)

Renal Morbidity Following Radical Cystectomy in Patients with Bladder Cancer
por: Schmidt, Bogdana, et al.
Publicado: (2022)

Outcomes by time to definitive chemoradiation treatment for patients with muscle-invasive bladder cancer
por: Kotha, Nikhil V., et al.
Publicado: (2022)

Combining Antiandrogens with Immunotherapy for Bladder Cancer Treatment
por: Besançon, Marjorie, et al.
Publicado: (2022)

The Significant Role of Depression in Elderly Patients with Bladder Cancer
por: Oserowsky, Alexander, et al.
Publicado: (2021)

Morbidity and Days Alive and Out of Hospital Within 90 Days Following Radical Cystectomy for Bladder Cancer
por: Maibom, Sophia L., et al.
Publicado: (2021)

Carboplatin Induction Chemotherapy in Clinically Lymph Node–positive Bladder Cancer
por: von Deimling, Markus, et al.
Publicado: (2023)

Living with Bladder Cancer: Self-reported Changes in Patients’ Functional and Overall Health Status Following Diagnosis
por: Ungerer, Garrett, et al.
Publicado: (2020)

Human Gut Mycobiome and Fungal Community Interaction: The Unknown Musketeer in the Chemotherapy Response Status in Bladder Cancer
por: Bukavina, Laura, et al.
Publicado: (2022)

Potential Carbon Savings with Day-case Compared to Inpatient Transurethral Resection of Bladder Tumour Surgery in England: A Retrospective Observational Study Using Administrative Data
por: Phull, Manraj, et al.
Publicado: (2023)

Darifenacin treatment for overactive bladder in patients who expressed dissatisfaction with prior extended-release antimuscarinic therapy
por: Zinner, N, et al.
Publicado: (2008)

Emerging perioperative therapeutic approaches in muscle invasive bladder cancer
por: Patil, Goutham, et al.
Publicado: (2022)

Fast skeletal muscle troponin activator CK‐2066260 increases fatigue resistance by reducing the energetic cost of muscle contraction
por: Cheng, Arthur J., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_kr06880ne57tqptt6tvovj3vom